Followers | 3 |
Posts | 40 |
Boards Moderated | 0 |
Alias Born | 06/20/2015 |
Tuesday, June 30, 2015 12:37:12 PM
Bulls make money - Bears make money - pigs get slaughtered.
I bought TPIV at .22, .25, + .26 in May.
I like the company, I like it long term, but when something is up 500% in a month, you KNOW there is going to be a lot of profit taking. Even if the market kept going up it would happen, when the whole market is selling, FEAR to protect huge profits kicks in even more .... do something before hand to protect yourself.
Staggered stop limits however you think is best when it's at 1.50.
1/4 of your position with an activation price of 1.20 so you don't get triggered on a little burb.
1/4 of your position with an activation price of 1.05.
1/4 of your position with an activation price of .95.
You have a ton of profit in your account and the value of your position is still more than you originally paid ... and it's basically free.
You want to own more, buy it back when it's cheap, but that's the question, what's cheap?
What's the psychology, the lower it goes, the more those last holders want to protect what's left of their profits because they are kicking themselves not selling sooner, so they sell and it goes even lower.
It's not going to go down back to .22 or .30 because at that point they say, screw it, I might as well just hold it. But somewhere between 2 1/2 to 3 1/2 times where it started it's run seems to happen often on these small stocks.
It started at .22, so a reasonable bottom would be in the .55 to .77 range.
PROTECT PROFIT and buy it lower if you want to hold a bunch long term.
Look at it like this, you buy a stock, it goes up more than 100% over a short period of time, put in a stop loss/limit on half of it. You get triggered .... FINE, you got back your original investment and keep half your shares FOR FREE.
Do that over and over and you wind up with a large portfolio of shares in stocks FOR FREE.
You've heard it before, it's the whole greed and fear thing, there's no shame in taking some profit.
Small stock or larger stock, same principal, I've got stop losses in for half shares on BLUE, up <600%, JUNO, ALNY etc, if it all gets triggered, FINE, I'll live with the profit and keep half the shares for free.
If you held this the whole time and your lucky enough to see 1.20 or 1.50 anytime soon, put in stop limits, because if it jumps up again, people will take profits AGAIN.
Recent MRKR News
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/17/2024 10:25:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:40:16 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:03:21 PM
- Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies • GlobeNewswire Inc. • 04/08/2024 11:00:39 AM
- Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results • GlobeNewswire Inc. • 03/25/2024 09:45:00 PM
- Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • GlobeNewswire Inc. • 03/22/2024 04:30:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:02:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:58:51 PM
- Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601 • GlobeNewswire Inc. • 01/22/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 01:30:48 PM
- Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization • GlobeNewswire Inc. • 01/08/2024 01:24:49 PM
- Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024” • GlobeNewswire Inc. • 12/21/2023 04:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 12:35:22 PM
- Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse • GlobeNewswire Inc. • 12/11/2023 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:37:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 10:03:53 PM
- Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/09/2023 10:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:31:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2023 11:10:46 AM
- Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse • GlobeNewswire Inc. • 09/11/2023 11:00:00 AM
- Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 08/30/2023 12:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:37:04 PM
- Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/14/2023 08:30:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:03:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2023 11:22:44 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM